-transparent.png){kind=logo}
Thirty children 8-13 years old, with perennial asthma and with a reversibility of greater than or equal to 20% in lung function (FEV1) were given a sustained-release preparation of terbutaline sulphate 5 mg twice a day and ordinary tablets 2.5 mg three times a day; each treatment lasted 1 week. The design of the study was double-blind, cross-over, with a randomized allocation of the drugs. Both drugs improved the lung function significantly. The children had significantly less coughing during the night when they took depot tablets than when they took ordinary tablets. The side effects were few with both treatments. Most of the patients preferred the depot tablets.
Related Publications
N Foged, and
A Høst, and
K Ljungholm
October 1981,
Allergy,
N Foged, and
A Høst, and
K Ljungholm
January 1987,
Ugeskrift for laeger,
N Foged, and
A Høst, and
K Ljungholm
October 1985,
Allergy,
N Foged, and
A Høst, and
K Ljungholm
October 2003,
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
N Foged, and
A Høst, and
K Ljungholm
May 1979,
Clinical allergy,
N Foged, and
A Høst, and
K Ljungholm
February 1988,
The Journal of allergy and clinical immunology,
N Foged, and
A Høst, and
K Ljungholm
November 1977,
JAMA,
N Foged, and
A Høst, and
K Ljungholm
July 1960,
Annals of allergy,
N Foged, and
A Høst, and
K Ljungholm
September 1973,
Acta allergologica,
N Foged, and
A Høst, and
K Ljungholm
January 1993,
Allergy,
